What Is Spinal Cord Stimulation?
A plain-language starting point. Use the tabs above to go deeper on any topic.
Spinal cord stimulation (SCS) is a procedure in which a small device — similar in concept to a pacemaker — delivers mild electrical pulses to your spinal cord. These pulses interfere with pain signals before they reach your brain, reducing how much pain you feel.
It does not fix the underlying cause of your pain. Think of it as changing the volume on your pain signal, not the source. For the right patient, it can meaningfully reduce pain and improve daily function when other treatments have not.
SCS is a reversible treatment. If it doesn't work or you change your mind, the device can be removed. This is one of its most important features compared to surgery that permanently alters anatomy.
Who Is It For?
SCS is generally considered for people who have chronic pain — typically lasting more than 3–6 months — that has not responded adequately to conservative treatments including physical therapy, medications, and injections. The strongest evidence supports SCS for:
Failed back surgery syndrome (FBSS) · Complex regional pain syndrome (CRPS) · Neuropathic leg pain · Painful diabetic neuropathy
Axial low back pain (without leg component) · Chronic neck pain with cervical radiculopathy · Refractory angina · Peripheral vascular disease pain
Fibromyalgia · Primary headache disorders · Active cancer as the pain source · Untreated significant depression or active substance use disorder · Patients unwilling or unable to operate the device
The Big Picture Before You Proceed
SCS is a significant decision. It involves two procedures (a trial and, if successful, a permanent implant), carries real risks, requires a psychological evaluation, and demands ongoing device management. Most insurance companies require documented failure of conservative care before they will approve it.
What honest success looks like
Roughly 50–60% of well-selected patients achieve at least 50% pain relief at one to two years. SCS rarely eliminates pain completely. The realistic goal is meaningful reduction — enough to improve sleep, activity, and quality of life — not a cure.
At five years, about half of initial responders maintain meaningful relief. This means roughly 25–30% of all implanted patients have durable long-term benefit. That is not a small number for a chronic pain population — but it means SCS is not for everyone, and understanding this before you commit matters.
A Brief History of SCS
Spinal cord stimulation is more than 50 years old. Understanding where it came from helps explain both its strengths and its limitations.
How Spinal Cord Stimulation Works
The simple explanation has been the same for 50 years. The full explanation is considerably more complex — and that complexity matters for understanding why different waveforms work differently.
The Simple Version: Closing the Gate
Your spinal cord carries pain signals from your body up to your brain. Spinal cord stimulation places electrical pulses near the spinal cord that interrupt or modify this signal before it reaches the brain. Less signal reaching the brain means less pain perceived.
Think of a busy freeway carrying pain signals to your brain. SCS doesn't close the freeway — it adds a toll booth that slows and reduces traffic. Fewer signals get through, and the ones that do arrive weakened.
Gate Control Theory (The Original Explanation)
Melzack and Wall's 1965 theory proposed that the spinal cord has a "gate" in an area called the dorsal horn. Large nerve fibers — the kind that carry touch and vibration sensations — can activate this gate and reduce the transmission of signals from smaller pain fibers. Traditional SCS (which produces a tingling sensation) works largely through this mechanism: the tingling you feel is your large fibers being activated, which closes the gate on pain signals.
Why Newer Waveforms Work Differently
Here is where it gets important: high-frequency SCS (10,000 Hz) and some other modern waveforms produce pain relief without any tingling sensation. This means gate control theory cannot fully explain them — the large fibers aren't being activated in the same way. Research suggests these waveforms work through different pathways:
Supraspinal mechanisms
High-frequency stimulation appears to alter pain processing in the brain itself — in areas like the anterior cingulate cortex and thalamus that handle the emotional and sensory aspects of pain. This may explain why HF10 can work even in patients whose pain has a significant central sensitization component.
Neurotransmitter changes
SCS increases the release of GABA (an inhibitory neurotransmitter) and serotonin in the dorsal horn, which dampens pain signaling. It also reduces excitatory neurotransmitters — glutamate and aspartate — that normally amplify pain. The net result is suppression of wide dynamic range (WDR) interneurons: the dorsal horn cells that become hyperactive in chronic neuropathic pain states and drive central sensitization. Calming WDR cells is one of the most important mechanisms by which SCS reduces neuropathic pain at its source. (Burton AW, in Raj's Practical Management of Pain, 4th ed.; Linderoth et al.)
Descending inhibitory modulation
The brain has its own pain-reduction system — pathways that descend from the brain down to the spinal cord and can reduce pain signaling from below. Burst stimulation in particular appears to activate these pathways, essentially triggering the body's own pain management system.
Anti-neuroinflammatory effects
Emerging evidence suggests SCS may reduce inflammation in the nervous system itself — reducing the activation of glial cells (the support cells of the nervous system) that contribute to chronic pain sensitization. This is an active area of research.
The fact that different waveforms work through different mechanisms means there is no single "best" SCS for everyone. The right choice depends on your specific pain pattern, the suspected mechanism driving your pain, and sometimes trial and error. A physician who offers only one waveform type may not be matching the therapy to your biology.
What SCS Does NOT Do
SCS does not repair damaged nerves, fix a herniated disc, reverse arthritis, or treat the underlying structural cause of pain. If you stop stimulation, your baseline pain will return — the device must remain active for ongoing benefit. This is a chronic therapy, not a cure. That is not a failure of the technology; it is simply what it is, and understanding it prevents disappointment.
Understanding Stimulation Parameters — What Your Doctor Is Adjusting
When your physician programs your device, they are adjusting several settings called stimulation parameters. Knowing what these mean helps you give better feedback at programming visits and understand why the same device can feel very different from one setting to another.
Ask your physician: "What frequency am I running at?" · "Can we adjust the pulse width to cover my [specific area]?" · "Why did my sensation change when I stood up?" · "Is my impedance normal?" Understanding these four questions puts you in a much better position to partner with your doctor in optimizing your therapy.
Waveforms & Devices
Modern SCS is not one therapy — it is a family of related approaches that differ in how they deliver stimulation, what you feel, and what conditions they target best.
Tap any waveform card to expand details. Your physician will recommend a specific approach based on your pain pattern. Knowing the options helps you ask better questions.
In plain English: Your spinal cord has a pain relay station — a layer of cells called the dorsal horn — where pain signals stop before continuing up to your brain. Tonic SCS floods this relay station with a steady electrical hum at 40–100 pulses per second. This overwhelms the "pain routers" (neurons called wide-dynamic-range, or WDR, cells) so they stop forwarding your pain signals. At the same time, it triggers your spinal cord's own chemistry: GABA (the "calm down" chemical) goes up; glutamate (the "alarm" chemical) goes down. Think of it as a constant signal that jams the pain radio frequency. Per Potere et al. in Minimally Invasive Surgical Procedures for Pain (Oxford, 2024), tonic SCS specifically targets the lateral discriminatory pain pathway — the one that tells your brain the location, quality, and intensity of pain.
Why you feel tingling: The same pulses that jam pain signals also activate the touch and vibration nerve fibers running alongside them. That tingling sensation is actually the therapy working — but it means the tingling must physically overlap your painful area for the device to be effective.
Position limitation: When you change position, the lead tips shift slightly, changing how much signal reaches the dorsal horn — so pain relief can vary moment to moment. This was the biggest driver behind newer waveform development.
In plain English: Your brain naturally fires in "bursts" — rapid clusters of pulses followed by silence — especially in the region that governs how emotionally overwhelming pain feels (the anterior cingulate cortex). BurstDR mimics this exact biological rhythm: 5 rapid spikes delivered in quick succession, 40 times per second, with a quiet rest period between each cluster. This pattern mirrors the dual-firing qualities of the thalamus. Most patients feel absolutely nothing — no tingling at all.
The key difference from tonic: Tonic SCS targets the pathway that tells you where pain is and how intense it is (the lateral discriminatory pathway). Burst targets the pathway that makes pain feel emotionally consuming and hard to ignore. Per Potere et al. (2024), burst activates the medial affective ascending pathway — the circuit that drives your brain's attentional and emotional response to pain. This is why burst can help when pain feels overwhelming even when the physical intensity is similar.
Key evidence: The SUNBURST trial (2018) showed ~68% of patients preferred burst over tonic. It may be especially effective for back-dominant pain, historically the hardest target for SCS.
Practical note: No tingling means no easy way to confirm it's working. That's intentional and normal — trust the process and your pain diary.
In plain English: Chronic pain neurons can get stuck in a "wind-up" loop — firing faster and faster, amplifying themselves into a self-sustaining alarm. At 10,000 pulses per second, HF10 overloads these cells directly at the dorsal horn. Per Potere et al. (2024), this creates a "reversible depolarization blockade" — the pain-processing cells get so saturated with electrical input that they physically cannot fire anymore. It's like tripping a circuit breaker on the pain alarm. When stimulation stops, the block fully reverses — nothing is damaged or permanently changed.
Why no tingling: Unlike tonic SCS, HF10 bypasses the touch and vibration fibers (Aβ axons) entirely and acts directly on dorsal horn pain cells and inhibitory interneurons. No touch fiber activation means no tingling sensation. The textbook also notes HF10 specifically suppresses the WDR "wind-up" phenomenon — the runaway amplification loop that makes chronic pain feel worse over time.
Key evidence: SENZA-RCT (2015): 74% vs. 53% back pain responders; 81% vs. 55% leg pain responders at 24 months vs. traditional SCS. SENZA-PDN (2021): 79% of painful diabetic neuropathy patients achieved ≥50% relief vs. 5% on medications alone.
Position independence: Because it doesn't rely on touching the right sensory fibers, it works the same whether you're sitting, standing, or lying down.
In plain English: Chronic pain isn't just a nerve cell problem — it's also a "support cell" problem. Glial cells (microglia and astrocytes) are the maintenance crew of your nervous system. In chronic pain, they become overactivated and act as pain amplifiers, keeping the alarm ringing even when there's nothing left to warn you about. Per Potere et al. (2024), DTM is the only SCS waveform specifically designed to target and reset these glial cells toward a healthier, less sensitized state — essentially working to undo the "pain memory" that chronic pain burns into the nervous system.
How it works: DTM runs four simultaneous electrical signals — one base signal and three "prime" signals, each at different frequencies and pulse widths — targeting six anatomic spots in the spinal cord at the same time. The textbook calls this "multiplexed" stimulation. Think of a symphony conductor directing four instrument sections simultaneously to address the pain orchestra from multiple angles at once, rather than playing one instrument at full volume and hoping for the best.
Evidence note: The DISTINCT trial demonstrated DTM non-inferiority to HF10. The glial cell modulation data is primarily from animal models — a promising mechanism, with the clinical evidence base still growing.
In plain English: Every other SCS device is "flying blind." It delivers pulses and has no idea how much is actually reaching the spinal cord. This matters because when you move — sit up, roll over, lean forward — the gap between your lead tips and the spinal cord shifts. The same setting that gives perfect relief lying down can overshoot when you stand (causing uncomfortable jolts) or undershoot (losing relief entirely). Per Potere et al. (2024), this is the fundamental problem with all open-loop SCS: it provides stimulation without any ability to sense or adjust to the spinal cord's actual response.
What closed-loop does differently: After each pulse, the spinal cord produces a tiny electrical echo called an ECAP (Evoked Compound Action Potential) — a measurable signal that the device can read. Closed-loop SCS listens to this echo thousands of times per second and adjusts the output automatically to maintain a consistent therapeutic level. Think of it as the difference between a fixed-volume radio and one that automatically adjusts for background noise in every room you walk into.
Key evidence: The EVOKE trial (2020, Abbott/Saluda) was the first SCS head-to-head trial to show superiority of one approach over another — closed-loop produced significantly better pain and disability scores than open-loop at 12 months. Medtronic's Inceptiv uses its own proprietary closed-loop sensing platform and is currently the smallest and thinnest SCS device available, with full-body 1.5T and 3T MRI conditional access. Both systems share the core principle of ECAP-based feedback; the specifics of sensing and adjustment differ by platform.
Note on acquisition: Abbott acquired Saluda Medical (the Australian company that developed Evoke) in September 2022. The technology now ships under Abbott branding.
In plain English: The dorsal root ganglion (DRG) is a relay station — a cluster of sensory nerve cell bodies sitting just outside the spinal canal, at the exit point of each spinal nerve. Every signal from a specific body region (your right foot, your left knee) passes through the DRG for that level before entering the spinal cord. Standard SCS casts a wide net across the entire dorsal column — great for covering your whole leg, but too imprecise for pain confined to one small area. DRG stimulation places a tiny lead directly at that specific gateway, intercepting signals from one region before they even enter the spinal cord's main highway.
Why it matters for focal pain: If your CRPS is limited to one foot, standard SCS has to stimulate a large spinal cord region to reach that foot — which also activates areas that don't hurt. DRG-S can target just that foot, just the knee, or just the groin with minimal spread to surrounding areas. This precision is especially valuable for conditions with well-defined, localized pain that standard SCS overshoots.
Key evidence: ACCURATE trial (2017): 81% vs. 56% treatment success for lower limb CRPS at 3 months vs. traditional SCS, with lower position-related variation.
Technical note: DRG leads are smaller and placed via a slightly different route than standard SCS leads. Cervical displacement is twice as likely with standard leads vs. DRG leads, making DRG-S more mechanically stable for focal targets.
Major Manufacturers
All devices below are FDA-approved. This table is factual and non-promotional. Ask your physician to explain their specific recommendation.
| Company | Key Devices | Signature Technology | Notable Feature |
|---|---|---|---|
| Medtronic | Inceptiv (flagship), Intellis Pro, Vanta (recharge-free) | DTM waveform, closed-loop ECAP sensing (Inceptiv) | Largest installed base; Inceptiv is smallest/thinnest SCS device; full-body 1.5T & 3T MRI conditional |
| Abbott | Proclaim XR, WaveWriter Alpha, Eterna, Axium (DRG) | Burst DR, Closed-loop ECAP, DRG-S | Only FDA-approved DRG system in the US; also offers closed-loop |
| Nevro | Senza Omnia, HFX iQ | HF10 (10 kHz) | Longest commercial track record for paresthesia-free HF; AI-guided programming |
| Boston Scientific | Spectra WaveWriter, Precision Montage | Multiple waveforms including burst and HF | Wide waveform options on one platform; strong MRI conditional options |
| Nalu Medical | Nalu Neurostimulation System | PSP (Pulsed Stimulation Pattern); tonic; miniaturized IPG with external wearable charger | No internal battery — eliminates battery replacement surgery. PSP blends narrow pulses, high-rate trains, and low-rate trains to engage multiple analgesic mechanisms simultaneously |
All major SCS manufacturers invest heavily in marketing to physicians and patients. Clinical trial data is often funded by the device manufacturer, which doesn't invalidate the data but does mean independent replication is important. When your physician recommends a specific device, asking "do you have a financial relationship with this company?" is a fair and legitimate question.
Which Waveform Is Right for This Patient?
An evidence-based decision guide — for patients and providers alike. Answer three questions to see which waveform the research most strongly supports, and exactly why the others weren't chosen.
The Process — Step by Step
From first appointment to long-term management, here is what the SCS journey actually looks like. Timelines vary significantly based on insurance and your individual clinical situation.
Your pain physician reviews your history, imaging, prior treatments, and performs a physical exam. Key questions: Have you completed adequate conservative care? Is your diagnosis appropriate for SCS? Are there any contraindications (pacemaker, active infection, anatomy that prevents lead placement)?
Most physicians and virtually all insurers require a psychological evaluation before SCS. This is not a barrier or a test to pass — it identifies factors that predict better outcomes (active coping, realistic expectations) and factors that predict worse outcomes (untreated depression, opioid dependence, catastrophizing). A good physician sees this as part of your care, not a box to check.
Your physician's office submits a prior authorization request to your insurance company. This includes your diagnosis, imaging, documentation of failed conservative care, medication trials, and the psychological evaluation. Timelines range from 2 weeks to 4 months depending on your insurer.
Missing documentation of conservative care failure, psychological evaluation not yet completed, or diagnosis code mismatch. Stay in contact with your physician's office — ask for the prior auth tracking number and check status every 2 weeks.
The SCS trial is a temporary test. Thin, flexible leads are placed through a needle into the epidural space under fluoroscopy (live X-ray guidance) and local anesthesia with light sedation. The leads exit your skin and connect to a small external battery you wear for 5–7 days. You go home the same day.
Keep a daily pain diary. Rate your pain morning and evening. Note which activities you can do that you couldn't before. Most physicians use ≥50% pain relief as the threshold for a successful trial. What matters most is whether the relief is meaningful to your daily life.
The temporary leads are removed in your physician's office. You and your physician review your trial diary and discuss whether to proceed.
If successful: Proceed to permanent implant — insurance requires documentation of trial success.
If unsuccessful: Leads are removed, nothing permanent has been implanted, and you explore other options. This is an important patient protection — the trial requirement prevents permanent implants in patients who won't benefit.
Done in an operating room under general anesthesia or deep sedation. Permanent leads are placed and the IPG (internal pulse generator — the battery/computer) is implanted under the skin, typically in your lower back or buttock.
Percutaneous leads (through a needle, like the trial) are minimally invasive but have higher migration rates. Paddle leads (placed surgically through a small laminotomy) sit more stably but require a larger procedure. Your physician will recommend based on your anatomy and history.
The device is programmed at your post-operative visit. Most patients require 2–4 programming sessions over the first few months. Think of it like adjusting a new hearing aid — the initial settings are a starting point, not a final answer. Modern systems increasingly allow remote adjustments via smartphone app.
Rechargeable IPG: Charge daily to weekly using a pad placed over the implant site. Battery life 7–10+ years before replacement surgery.
Non-rechargeable IPG: No charging, but requires surgical battery replacement every 3–7 years.
MRI: Most modern devices are MRI-conditional with specific precautions. Always tell any imaging facility, emergency room, or treating physician that you have an SCS implant before any procedure.
Does It Work? The Evidence
Honest numbers from published literature. These are population averages — your individual result will depend on your diagnosis, device selection, and how well you are selected as a candidate.
Most SCS trials define "success" as ≥50% pain relief — a meaningful reduction, not elimination of pain. "Responder rates" tell you the percentage of patients who achieved that threshold. They do not tell you by how much the average patient's pain improved.
Overall Results at 1–2 Years
Evidence by Condition
What the evidence doesn't always tell you
Most SCS trials are funded by device manufacturers. This doesn't automatically invalidate the results, but industry funding is associated with more favorable outcomes in medical research generally. Independent replication studies often show more modest results.
Most trials study carefully selected patients at academic centers — healthier, less complicated than the average chronic pain population. Your own result may vary based on how similar you are to trial participants.
Very few SCS trials use sham (placebo) controls, because it is difficult to create a convincing SCS placebo. This means the true placebo effect of SCS is unknown, and some portion of benefit in any trial may be non-specific.
Risks & Complications
SCS is generally safe, but it is a surgical procedure with real risks. Understanding these before you commit is part of informed consent.
Complication rates in the literature vary widely — from 14% to 43% overall — depending on the study era, center experience, device generation, and how "complication" is defined. The rates below reflect figures from Potere et al. in Minimally Invasive Surgical Procedures for Pain (Oxford, 2024), which represent contemporary practice with modern anchoring techniques and sterile protocols. Older studies and general registries (such as Table 54-1 in Raj's Practical Management of Pain, 4th ed.) report lead migration in 7–14% and breakage in 0–23% across multiple series, confirming wide variability by era and center. Experienced high-volume centers tend toward the lower end of all ranges.
Technical (Hardware) Complications
Biologic Complications
These are often reported together in older literature, which creates confusion. They carry very different clinical significance. Superficial wound infections can usually be treated with antibiotics. Deep infections almost always require complete hardware removal.
Reducing Your Infection Risk — What You Can Do Before Surgery
The NACC (Neurostimulation Appropriateness Consensus Committee) of the International Neuromodulation Society has published evidence-based recommendations for infection prevention. Several of these are things you — not just your surgical team — can directly influence.
Revision and Explant Rates
Revision Surgery
Per Potere et al. (2024), complication rates requiring surgical revision are reported between 23% and 33% across studies. This includes lead repositioning, connector repair, and IPG replacement — not all are emergent or unexpected. This is the number that most accurately reflects the "total surgical burden" of SCS over its lifetime, and it is the number patients should understand before committing.
Explant Rate
The textbook (Potere et al., 2024) cites an explant (complete removal) rate of approximately 11% across published studies — meaningfully lower than the 20–30% figures that appear in some older registry-based estimates. The difference reflects study era, follow-up duration, patient selection, and the improvement in device technology over time.
What drives explant: Infection (most urgent), loss of efficacy, hardware failure, patient preference, or need for MRI incompatible with the device. Explant surgery itself is generally straightforward. Some patients go on to successful reimplantation after a waiting period.
MRI Restrictions
Most modern SCS systems are MRI-conditional — MRI is permitted under specific conditions (field strength limits, certain coil types, device switched to MRI mode). This is not a blanket prohibition, but requires coordination with the imaging facility. Always disclose your SCS implant before any imaging procedure, and in any emergency, immediately inform treating staff.
The honest bottom line on complications
SCS is a safe procedure at experienced centers with modern techniques and protocols. The most serious individual complication — deep infection — occurs in roughly 1 in 1,000 procedures. Lead migration, the most common complication, requires revision in 11–13% of patients but is rarely dangerous.
The more meaningful number for long-term planning is the revision rate: roughly 1 in 4 patients will need at least one additional hardware-related procedure over the lifetime of the device. This is the nature of an implanted electromechanical device in a moving body, and understanding it upfront leads to better decision-making and less disappointment.
Source: Potere B, Hussain N, Deer T, Abd-Elsayed A. Chapter 19 in: Sayed D et al., eds. Minimally Invasive Surgical Procedures for Pain. Oxford University Press; 2024. pp. 313–315.
Insurance & Coverage
Coverage for SCS is generally available but requires meeting specific criteria and navigating a pre-authorization process that can take weeks to months.
Coverage policies change frequently. What follows reflects common criteria as of mid-2026. Always verify your specific policy with your insurance company and your physician's billing team.
Medicare Coverage
Commercial Insurance
The Pre-Authorization Process
Includes: ICD-10 diagnosis codes, imaging, office notes documenting conservative care failure, medication trial records, psychological evaluation, and a letter of medical necessity. Documentation quality determines whether you are approved on first submission.
A non-physician reviewer checks documentation against coverage criteria. Most delays come not from you not qualifying — but from documentation being flagged as incomplete.
Your physician speaks directly with the insurer's medical director. Overturn rates after peer-to-peer review are significant — often 40–60% of initial denials are reversed. Do not give up after a first denial without requesting this step.
Written appeal with additional clinical documentation. If denied again: external independent review, and in some states, state insurance commissioner complaint. Your physician's office should have an appeals team or can refer you to a patient advocate.
Cost Without Insurance
1. Ask for the prior authorization status number — track it yourself, don't only rely on the office. 2. Get written confirmation of insurance approval before your trial date. 3. Confirm your out-of-pocket responsibility — facility, anesthesia, and device fees may bill separately. 4. Ask specifically whether reprogramming visits are covered.
5. If denied: do not cancel your appointment with your physician. Schedule a peer-to-peer review first.
Questions to Ask Your Doctor
Walk into your consultation prepared. A good physician will welcome every one of these.
You will not remember everything in the consultation room. Write down the answers your physician gives you. If they can't or won't answer a question, that is information too.
About Your Candidacy
- 1Why do you think I am a good candidate for SCS specifically, versus other options I haven't tried?
- 2What is your honest estimate of my likelihood of success given my specific diagnosis and history?
- 3Do I have any factors — psychological, anatomical, or clinical — that would reduce my chances of a good outcome?
- 4Is there anything I should do before the trial to improve my chances of success?
About the Device Recommendation
- 5Which waveform do you recommend for my pain pattern, and why that specific one over others?
- 6Which company's device are you planning to use, and what is your reasoning?
- 7Do you have any financial relationship with that device company — speaking fees, consulting, training programs? (This is a fair question. A physician with a relationship is not automatically wrong, but you deserve to know.)
- 8Am I a candidate for paddle leads, and what are the tradeoffs versus percutaneous leads for my anatomy?
About Your Physician's Experience
- 9How many SCS procedures do you perform per year?
- 10What is your personal success rate — ≥50% relief — for patients with my specific condition?
- 11What is your infection rate, and what is your protocol if I develop an infection after implant?
- 12How often do your patients require revision surgery within the first 2 years?
About Risks and Alternatives
- 13What happens if the trial fails? What would my next options be?
- 14If I get an infection and need the system removed, what does that process look like, and how long before I could consider reimplant?
- 15What are the specific MRI restrictions for the device you're recommending? What do I do if I need an emergency MRI?
- 16What is the realistic plan if my pain relief decreases significantly after one or two years?
About Insurance and Logistics
- 17Has my insurance been confirmed, and do you have written authorization before we schedule the trial?
- 18What is my estimated out-of-pocket responsibility for the trial and for the permanent implant?
- 19Are reprogramming visits covered by my insurance, and how often will I need them?
- 20What long-term follow-up do you provide — will I always have access to programming support?
A final word
SCS can be a life-changing therapy for the right patient. It can also be a source of significant frustration and additional procedures for the wrong patient or a patient with inadequate expectations. The single best predictor of a good experience is going in with honest information — understanding what you're hoping for, the realistic probability of achieving it, and what happens if it doesn't work.
You now have the information most patients don't get. Use it.
Pain Rosetta is an independent patient education resource with no affiliation with any device manufacturer, hospital system, or insurance company. All evidence cited is from published peer-reviewed literature. This page does not constitute medical advice. Always consult a qualified physician for evaluation and treatment decisions.
Content reviewed by an interventional pain physician · Last updated July 2026
Visuals & Videos
See what the device looks like, how it's placed, and watch manufacturer animations explaining each therapy. All links open in a new tab.
The Device — What Goes Where
An SCS system has three main parts. Everything below the skin is shown here.
Component Close-Ups
Watch It in 3D — Curated Video Resources
These links open official manufacturer and medical education content in a new tab. All content is publicly available.
Official Patient Education Pages
Every major manufacturer has patient-facing 3D content on their websites. These are the best sources for interactive device visualizations.
All manufacturer videos are educational but also promotional. They show devices working well, not complications or failures. Use these to understand what the hardware looks like and how procedures work — not to evaluate whether a specific brand is right for you. That conversation belongs with your physician.
References & Verified Resources
Every claim on this page is grounded in published peer-reviewed literature. Below are the primary sources, plus verified contact information for professional organizations, patient advocacy groups, and manufacturer support lines so you can confirm this information is legitimate.
Clinical Trials Cited
All PubMed links open in a new tab and lead directly to the published abstract. PubMed is the U.S. National Library of Medicine's public database — free to access.
Melzack R, Wall PD. Pain mechanisms: A new theory. Science. 1965;150(3699):971–978.
The foundational paper behind all SCS. Proposed the "gating" mechanism in the spinal cord's dorsal horn.
Kumar K, et al. Spinal cord stimulation versus conventional medical management for neuropathic pain: a multicentre randomised controlled trial in patients with failed back surgery syndrome. Pain. 2007;132(1–2):179–188.
Landmark RCT: 48% of SCS patients achieved ≥50% leg pain relief vs. 9% in controls at 6 months.
Kapural L, et al. Novel 10-kHz High-frequency Therapy (HF10 Therapy) Is Superior to Traditional Low-frequency Spinal Cord Stimulation for the Treatment of Chronic Back and Leg Pain: The SENZA-RCT Randomized Controlled Trial. Anesthesiology. 2015;123(4):851–860.
74% vs. 53% back pain responders; 81% vs. 55% leg pain responders at 24 months favoring HF10.
Deer TR, et al. Dorsal Root Ganglion Stimulation Yielded Higher Treatment Success Rate for Complex Regional Pain Syndrome and Causalgia at 3 and 12 Months: A Randomized Comparative Trial. Pain. 2017;158(4):669–681.
81% vs. 56% treatment success for lower limb CRPS at 3 months favoring DRG stimulation.
Deer TR, et al. Success Using Neuromodulation With BURST (SUNBURST) Study: Results From a Prospective, Randomized Controlled Trial Using a Novel Burst Waveform. Neuromodulation. 2018;21(1):56–66.
~68% of patients preferred burst over tonic stimulation in crossover design.
Mekhail NA, et al. Long-term Safety and Efficacy of Closed-Loop Spinal Cord Stimulation to Treat Chronic Back and Leg Pain (Evoke): A Double-Blind, Randomised, Controlled Trial. Lancet Neurology. 2020;19(2):123–134.
First RCT demonstrating superiority of one SCS approach over another: closed-loop outperformed open-loop at 12 months.
Petersen EA, et al. Effect of High-frequency (10-kHz) Spinal Cord Stimulation in Patients with Painful Diabetic Neuropathy: A Randomized Clinical Trial. JAMA Neurology. 2021;78(6):687–698.
79% of HF10 patients achieved ≥50% relief vs. 5% on medications alone at 6 months.
Textbooks Referenced
Potere B, Hussain N, Deer T, Abd-Elsayed A. Percutaneous Spinal Cord Stimulator Trial; and associated chapters. In: Sayed D, Abd-Elsayed A, Falowski S, Deer T, eds. Minimally Invasive Surgical Procedures for Pain. Oxford University Press; 2024.
Primary source for waveform mechanism descriptions on this page. Chapters on SCS trial, permanent implantation, and DRG stimulation. Published by Oxford University Press (peer-reviewed academic publisher).
McMahon S, Koltzenburg M, Tracey I, Turk D, eds. Wall & Melzack's Textbook of Pain, 6th ed. Elsevier; 2013.
The definitive reference text on pain neuroscience. Foundation for gate control theory descriptions and central sensitization content on this page.
Deer TR, Provenzano DA, Hanes M, Pope JE, et al. The Neurostimulation Appropriateness Consensus Committee (NACC) Recommendations for Infection Prevention and Management. Neuromodulation. 2017;20(1):31–50. DOI: 10.1111/ner.12565
International Neuromodulation Society consensus guidelines on infection prevention and management for SCS and neuromodulation devices. Source for infection rate ranges (3.4–4.6% in systematic reviews), pathogen data (Staphylococcus species; MRSA), infection site breakdown (IPG pocket 54%; connector 17%; back incision 8%), risk factor quantification (diabetes 3.5×; obesity 2.2×; steroid use 1.7–3.4×), epidural abscess staging and mortality data (10–23%), MRSA decolonization protocol evidence (mupirocin + chlorhexidine; 60% SSI reduction), and patient-facing preoperative recommendations throughout the Risks tab.
Burton AW. Spinal Cord and Peripheral Nerve Stimulation (Chapter 54). In: Benzon HT, Rathmell JP, Wu CL, Turk DC, Argoff CE, eds. Raj's Practical Management of Pain, 4th ed. Mosby/Elsevier; 2008.
Source for evidence-grade classifications by diagnosis (CRPS: Grade A; FBSS: Grade B; peripheral ischemia: Grade A), complication frequency data (Table 54-1), programming parameter ranges, and neurochemical mechanism detail (GABA, serotonin, WDR interneuron suppression). Also source for cost-effectiveness analysis: SCS for CRPS recoups initial device cost within approximately 2.1 years vs. conventional care (Kemler & Furnee analysis cited therein).
Medicare Coverage — Verify It Yourself
The official Medicare coverage document for spinal cord stimulation is LCD L38076 ("Neurostimulators for Pain Control"). Go to the CMS Medicare Coverage Database, click "LCD," and search for L38076. Includes exact criteria, covered diagnoses, and documentation requirements.
TTY: 1-877-486-2048 · Open 24/7 · medicare.gov
Professional Medical Organizations
These organizations set the clinical guidelines used by physicians who perform SCS. Their websites provide independently verified information about neuromodulation and pain management.
Patient Advocacy & Support Organizations
These are independent, non-profit organizations that advocate for patients with chronic pain. They have no financial relationships with device manufacturers.
Manufacturer Patient Support Lines
If you already have an implanted device and need technical support, programming help, or MRI clearance questions, contact your device manufacturer directly. These are official patient support lines.
About Pain Rosetta
How to verify this page is what it says it is
Pain Rosetta is an independent patient education project created by an interventional pain physician (D.O., board-certified) with no financial relationships with device manufacturers, hospital systems, or insurance companies. There are no ads, no referral fees, and no sponsored content.
Every clinical claim on this page cites a specific peer-reviewed source accessible via the PubMed or DOI links above. Every organization listed has an independently verifiable web presence. If anything on this page appears inaccurate, please compare it against the cited sources.
This page is not a substitute for medical advice. The information here is designed to help you have a better conversation with your physician — not to replace that conversation.
Peripheral Nerve Stimulation
A complete, honest patient guide — how PNS works, which conditions it treats, what the trial is like, evidence, and insurance — is coming soon to Pain Rosetta.
- How PNS differs from SCS
- Devices: Nalu, SPR Therapeutics, Bioness, Abbott
- Conditions: occipital neuralgia, post-amputation pain, shoulder pain, knee OA
- Temporary vs. permanent implants
- What the trial period involves
- Evidence & clinical trials
- Insurance and prior authorization
SI Joint Fusion
A complete guide to sacroiliac joint fusion — anatomy, diagnosis, minimally invasive techniques, evidence, and what recovery looks like — coming soon.
- What the SI joint is and why it hurts
- How fusion differs from injections
- Devices: iFuse (SI-BONE), Rialto (Medtronic), Catamaran
- INSITE, iMIA, and SIFI clinical trial results
- Minimally invasive vs. open approach
- Recovery timeline and what to expect
- Insurance criteria (Medicare LCD)
MILD Procedure
A patient guide to the Minimally Invasive Lumbar Decompression (MILD) procedure for lumbar spinal stenosis — how it works, who qualifies, and what the evidence shows — coming soon.
- What lumbar spinal stenosis is
- How MILD removes the ligamentum flavum without general anesthesia
- Who qualifies (neurogenic claudication, MRI criteria)
- MILD RCT, ENCORE, and registry study results
- Comparison to laminectomy and epidural steroids
- What the procedure day looks like
- Insurance and prior authorization